Assoc. Prof. Serhii Artiukh

Biography

Serhii Volodymyrovych Artiukh combines clinical oncology, research, medical education and the organisation of specialised care. Training and practice in family medicine and radiology preceded his specialisation in clinical and radiation oncology, shaping an integrated approach to diagnosis, treatment planning and patient support.

He is a senior researcher at the State Institution “Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine”, teaches at Kharkiv National Medical University, and contributes to the development of specialised oncology services as medical director of Brigid Onco LLC.

During the full-scale war, Serhii Artiukh was involved in maintaining oncology care in Kharkiv amid hostilities, power disruptions and severe logistical constraints. This experience provides a practical foundation for his work on the resilience of high-technology medical services.

Expertise

• clinical and radiation oncology;
• high-dose-rate brachytherapy, including prostate cancer treatment;
• conformal radiotherapy and optimisation of fractionation schedules;
• head and neck cancer treatment, radiomodification and chemoradiotherapy;
• medical imaging, clinical topometry, navigation and personalised dose control;
• assessment of anticancer treatment effectiveness and toxicity;
• digital technologies and artificial-intelligence methods in oncology;
• resilient oncology services, medical education and health-system operation during war and crisis.

TNESC Leadership

At TNESC, Serhii Artiukh is a Practical Core member and serves as an expert in public health, education and science, digital transformation, and international academic cooperation. His contribution focuses on translating verified research into clinical practice, developing precision radiotherapy and digital medical tools, and designing continuity-of-care models for wartime and recovery settings.

Mentorship and Training

Serhii Artiukh combines teaching with clinical and research work. As an associate professor and researcher, he contributes to the education of future physicians, the professional development of early-career specialists and a clinically oriented research environment. The approved source packet also records his participation in academic assessment as an official opponent for a doctoral dissertation in clinical oncology.

Projects

Since 2014, Serhii Artiukh has participated in research programmes of the National Academy of Medical Sciences of Ukraine as an investigator and principal responsible investigator. Verified topics include:

• algorithms for conventional and conformal radiotherapy planning;
• personalised absorbed-dose control using in vivo dosimetry;
• COX-2 inhibitors in combined radiotherapy and anti-angiogenic treatment;
• genotoxic and cytogenetic effects of radiotherapy;
• optimisation of topometric preparation for head and neck cancer treatment;
• individualised anticancer therapy after COVID-19;
• chemoradiotherapy for head and neck squamous cell carcinoma in extreme conditions;
• the role of NF-kB in radioresistance and chemoradiotherapy effectiveness.

He has also served as a co-investigator or coordinator in international multicentre studies in gynaecological oncology, bladder cancer and head and neck cancer, including the KEYLYNK, LEAP, KEYNOTE, RUBY, FIRST and CEL-SCI programmes.

Publications and Professional Outputs

The verified source packet contains 43 scientific and professional outputs: journal articles, patents, a patent application and collective monographs. They address head and neck radiotherapy, in vivo dosimetry, biomarkers of radiation exposure, medical monitoring, molecular mechanisms of radioresistance, oncology care during war and high-dose-rate brachytherapy.

Selected outputs include research on FDXR as a biomarker of in vivo radiation exposure in Scientific Reports; a study of DNA-damage-response gene transcription during radiotherapy in Cancers; publications on NF-kB, VEGF, COX-2 and PGE-2; clinical work on prostate brachytherapy; patents for radiotherapy planning and treatment methods; and monographs on radiosensitisation and patient stratification in medical monitoring systems.

Selected Bibliography

• S. V. Artiukh et al. FDXR is a biomarker of radiation exposure in vivo. Scientific Reports. 2018. Vol. 8. Article 684.
• S. V. Artiukh et al. A Method for Assessing the Risks of Complications in Chemoradiation Treatment of Squamous Cell Carcinoma of the Head and Neck. The Open Bioinformatics Journal. 2021. Vol. 14. Pp. 138–143.
• S. V. Artiukh et al. Agent-oriented data clustering for medical monitoring. Radioelectronic and Computer Systems. 2022. No. 1(101). Pp. 103–113.
• S. V. Artiukh et al. Transcriptional Dynamics of DNA Damage Responsive Genes in Circulating Leukocytes during Radiotherapy. Cancers. 2022. Vol. 14, no. 11. Article 2649.
• S. V. Artiukh et al. Computational intelligence methods to patients stratification in the medical monitoring systems. Radio Electronics, Computer Science, Control. 2023. No. 1.
• S. V. Artiukh et al. Influence of conformal radiotherapy in combination with radiomodifiers on the content of VEGF, COX-2, and PGE-2 in blood serum of patients with head and neck squamous cell carcinoma. Experimental Oncology. 2024. Vol. 46, no. 3. Pp. 253–259.
• S. V. Artiukh et al. Особливості надання променевої терапії пацієнткам з раком молочної залози в умовах обмеженого доступу до планового лікування під час воєнних дій. Emergency Medicine (Ukraine). 2025. Vol. 21, no. 8. Pp. 777–782.
• S. V. Artiukh et al. Брахітерапія передміхурової залози як варіант органозберігального лікування локалізованого раку в реаліях України: аналіз результатів та перспективи розвитку. Ukrainian Radiological and Oncological Journal. 2025. Vol. 33, no. 4. Pp. 428–445.